In 1660, Hafenreffer wrote, "Itching is an unpleasant cutaneous sensation which provokes the desire to scratch" [1], a definition that not only has remained unchanged for centuries, but also marks itching and scratching as interdependent symptoms. The complex generation of itch and the automatic scratch response lead to the clinically challenging itch-scratch cycle.
Introduction
In 1660, Hafenreffer wrote, "Itching is an unpleasant cutaneous sensation which provokes the desire to scratch" [1], a definition that not only has remained unchanged for centuries, but also marks itching and scratching as interdependent symptoms. The complex generation of itch and the automatic scratch response lead to the clinically challenging itch-scratch cycle.
In the UK, approximately 80% of skin-related general practice consultations have itch as an underlying symptom [2] . Despite being one of the most common presenting dermatological symptoms, itching continues to challenge health care professionals because it is notoriously difficult to control [3] . Research continues into fully exposing the origins of this mysterious symptom and is steering its focus toward understanding the mechanisms of chronic itch.
This review attempts to answer the 2-part question, "Why do we itch and scratch?" by first touching on the history of itchy disease, the neurobiology of itch, and the 4 different clinical origins of itch: pruritogenic, neurological, neuropathic, and psychological. In addition, we explore the reflex of scratching and discuss whether it should be deemed a protective mechanism or rather an uncontrollable human impulse that evolution has rendered obsolete.
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Neurogenic Itch
Neurogenic itch, sometimes also referred to as systemic itch, is an itch that originates from organs other than the skin, without evidence of peripheral nerve damage or psychiatric roots [3] . Conditions frequently causing neurogenic itch are hematological disease, hepatobiliary disease, and chronic kidney disease [47] .
Hematological itch, seen in polycythemia vera, myeloproliferative disorders, or myelofibrosis, is often aquatogenic, occurring after a warm shower. Indeed, this itch is shown to be subdued by selective serotonin reuptake inhibitors; this response is hypothesized to be due to the upregulation of serotonin receptors creating a higher activation threshold; however, a confirmed mechanism is unknown [42, 45, 48] .
Cholestatic pruritus, seen in a variety of hepatocellular disorders, is thought to be due to the accumulation of bile salts that trigger histamine and lysophosphatidic acid release [49] . Lysophosphatidic acid is a powerful pruritogen as seen by the correlation between high serum levels and pruritus in patients [49] [50] [51] . Furthermore, cholestatic patients also have higher levels of endogenous opioids, possibly produced by the diseased liver and thought to contribute to systemic itch [52] . Indeed, administration of oral or intravenous opioid antagonists has been shown to significantly reduce scores on visual analogue scales of pruritus in patients with hepatobiliary disease [53] [54] [55] .
Similarly, more than 40% of patients with chronic kidney disease present with pruritus thought to originate from endogenous opioid upregulation [56] . Therefore, opioid antagonist therapies are trialed; however, higher quality trials are still needed to confirm the efficacy, safety, and addictive risks of these treatments [28, [57] [58] [59] .
Neuropathic Itch
The third etiology of itch is neuropathic, which refers to a neuronal origin of itch, occurring due to damaged central or peripheral afferent nerves. This type of itch is often accompanied by localized neuropathic symptoms, such as pain and paresthesia, or as part of a larger neurological diagnosis, such as multiple sclerosis [3, 60] . The mechanisms of this itch are often debated between erroneous stimulation of pruritic signals or damage of itch-inhibiting neurons [3] .
Overall, neuropathic itch presents in a variety of ways, from
A Brief History of Itch
Itch has troubled humanity throughout history. Dating back to the BC era, ancient Greeks and Egyptians recorded instances of itchy rashes, akin to today's infectious pruritus, that coincided with outbreaks of diarrhea, smallpox, and hookworms [4] . In 121 AD, Roman historian Suetonius also made reference to records of atopic dermatitis. He wrote of Emperor Augustus's atopic symptoms consisting of seasonal allergies, chronic itch, and dry, hardened patches of skin [5] . Subsequently, in 1726, Daniel Turner, the alleged first British dermatologist, described itchiness as a symptom that is "impure," beginning as a contagious process through the skin, which then spreads into the bloodstream [6] , possibly reflecting the stark religious influences of 18th-century medicine.
In some of the earliest records of modern dermatological medicine, Dr. Hazen (1915) described an impressive array of various skin pathologies, which are much the same as those seen today, however, with the depth of knowledge into their etiology being far more primitive [7] . The symptom of itchiness was habitually mentioned by patients, but its purpose was largely diagnostic in nature. In contrast, itchiness today remains a prominent symptom; however, the focus has shifted away from diagnosis and rather toward management [8] [9] [10] [11] .
In an effort to successfully manage pruritus, current research has focused on understanding the cellular pathways and the neurobiology of itch, with the objective of identifying target mediators that can be inhibited to relieve itch. For this reason, to answer the question, "Why do we itch?" the following sections will concisely discuss the 4 different underlying etiologies of itch.
Etiology of Itch
The human etiology of itch can be divided into pruritoceptive (dermatological), neurogenic (systemic), neuropathic, and psychogenic mechanisms [12, 13] .
Pruritoceptive Itch
A pruritoceptive, also known as dermatological, itch refers to the cellular mechanisms originating from layers of the skin to produce the somatic sensation of itch [3] . This pathology of itch remains the most common cause of pruritus in dermatology, and a vast amount of research has been done to understand and target therapies against it. Histamine was the first and remains the most explored pruritogen [14] [15] [16] ; in fact, antihistamines, such as levocetirizine, are often used successfully for the treatment of histamine-induced itch with an observed dose-response pattern [17] . However, antihistamines often give poor relief to chronic itch, for example in atopic dermatitis [18] , reinforcing the theory that there 
Psychogenic Itch
Psychogenic itch, the fourth etiology of itch, is a diagnosis of exclusion whereby another reason for itch is not found and mental health symptoms are present [3] . Psychogenic itch can often present with a psychiatric condition such as ; more pruritogenic than histamine in rats [43] ; serotonin injection induces pruritus in healthy patients [44] ; SSRIs shown to reduce chronic itch [45] ; ondansetron effective in cholestatic itch [46] 5-HT = serotonin; BNP= type b natriuretic polypeptide; ET = endothelin; IL-31RA = interleukin-31 receptor A; NK1 = neurokinin 1; OSMR = oncostatin M receptor; PAR= protease activated receptors; SSRI = selective serotonin reuptake inhibitor; TRPV1 = transient receptor potential villanoid 1.
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can transmit both pain and itch. If itch fibers in humans are polymodal, pain and itch must be differentiated more proximally; in fact, functional magnetic resonance imaging of the cortex has shown different activation areas [93, 94] .
Owing to the unethical nature of isolating spinothalamic sections in humans, unanswered questions remain about the role central ascending tracts partake in the perception of itch [95] . Nonetheless, knowledge that itch is transmitted by polymodal fibers is useful for the discovery of new therapies to combat chronic itch by trialing treatments used to break other hypersensitivities such as chronic pain or chronic cough cycles [61, 62, 96] .
Pathways of itch conduction and perception vary between humans and animals, suggesting that evolution may have devolved our separate pathway for itch. This could mean that itching may have been beneficial in animals who needed to "scratch-away" invaders (such as ticks and fleas) from their fur coat, a response that was no longer necessary once we had lost our primate-like hairy coat. This would explain why scratching can often be traumatic to human skin, whereas in furred animals it is required to rid the hairs of invaders and does not often damage their underlying skin.
Scratching
Scratching is often presumed to provide mechanical protection and subsequent inflammatory defense against harmful elements on the skin [97, 98] . However, scratching is also known to disrupt the epidermal barrier and facilitate infection [11] . Another view is that we scratch because we want to relieve the itch by causing localized pain that will suppress the intolerable itch, suggesting we prefer to withstand mild pain rather than be itchy [98] . Moreover, relieving an itch via scratching often causes a feeling of pleasure, thought to be due to both the riddance of the intolerable itch and the release of serotonin during scratching [99] .
Although our body seems to be "rewarded" for scratching an itch, it is well known that repeated scratching prolongs and aggravates the itch in various situations ranging from mosquito bites to atopic dermatitis [100] . Indeed, itchy stimuli activate the striatum and limbic region of the cortex, the reward and motivation centers, causing a reward-driven but altogether damaging itch-scratch cycle [101] . In addition, when we advise patients to stop scratching, we are fundamentally implying that the human scratch response is innately flawed. Patients aware of this detrimental itchscratch cycle continue to scratch, knowing it will only provide short-term relief.
Scratching has been reported to increase at night due to itch being exacerbated by higher circadian skin temperatures, increased trans-epidermal water losses, reduced corticosteroid
Neurobiology of Itch
As shown above, itch is triggered by 4 distinct mechanisms either centrally or peripherally. To understand how pruritogenic stimulation is transmitted to the brain and interpreted, we must study the different afferent (mechanical, thermal, and polymodal) neurons, how they respond to pruritogens, and which parts of the cortex they activate [69] [70] [71] [72] .
Previously, itch was believed to be a mild form of pain transmitted by the same nociceptive fibers and suppressed by greater painful (mechanical or thermal) stimuli [73] . This "intensivity" theory was later discredited by evidence from both humans and animals. Not only did increasing the intensity of an itchy stimulus not convert to a painful stimulus, but also a distinct subpopulation of nerves were shown to be activated by pruritogenic vs painful stimuli [74] [75] [76] . Similarly, itch triggers a targeted scratch response, while pain generates an unrelated withdrawal reaction, suggesting itch and pain are not transmitted via identical neurological pathways.
Currently, newer theories exist about how itch is transmitted to the brain, specifically the "selectivity" and "labeledline" theories. The "selectivity" theory states that itch fibers are more selective toward pruritogenic stimuli, but are polymodal, also transmitting pain. In contrast, the "labeled-line" theory supports the existence of afferent fibers exclusively responsive to pruritogenic stimuli [3] . To explore both theories, research has used animal experiments to alter the expression of presumed pruritoceptive mediators and evaluate variations in scratch response [77] [78] [79] [80] [81] [82] [83] .
Cats have been shown to have afferent nerve fibers solely activated by pruritogens both peripherally and in the spinothalamic tract [84] . Moreover, mice possess afferent neurons expressing specific pruritogenic modulators such as
Mas-related-G-protein-coupled receptor (MrgprA3+) and gastrin-related peptide (GRP), the latter expressed only in a small subset of dorsal ganglia and in the lamina I tract of the spinothalamic cord [85, 86] . The genetic removal of these receptors significantly reduces the scratch response, but not pain response. This evidence essentially supports that in animals itch is probably mediated via the "labeled-line" theory and that their itch and pain neurons are distinct [86, 87] .
In humans, more than 90% of afferent fibers are polymodal; they respond to 2 or more types of stimuli [75, 88] .
Skin stimulation has shown that different fibers responded to histamine and non-histamine-induced itch, suggesting that humans possess distinctive peripheral pathways for the transmission of different pruritogens [89, 90] . These fibers have been shown to go on to activate separate subsets of the spinothalamic tract; however, all these pruritogenic pathways were also activated by painful stimuli [91, 92] . This finding suggests that in humans, itch is probably transmitted in line with the "selectivity theory" using polymodal fibers, which logical pruritus can often be subdued by the use of tricyclic antidepressants or selective serotonin reuptake inhibitors, by atopic dermatitis [115] [116] [117] [118] . Neurokinin 1 antagonists, mediating the substance P pathway, have recently shown a dose-dependent decrease of baseline pruritic visual analogue scales after a few weeks of use [119, 120] . In atopic dermatitis, monoclonal antibodies targeting interleukin 4 and 13 have also shown promise in increasing the quality of life of patients through itch reduction [121] . These innovative therapies to combat itch are being revealed thanks to an increased understanding of its different pathways and transmitters. Nevertheless, additional data are required to explore the success rates, cost-effectiveness, and long-term adverse effects of innovative therapies in patients suffering from chronic itch.
Conclusions
An itch can arise from a variety of underlying mechanisms and is transmitted to the cortex via a subset of polymodal fibers that are more selective toward pruritogens. Pruritic skin conditions continue to compromise a large psychological and financial burden, with up to 20% of children in Britain suffering from eczema [122] and 3% of adults from psoriasis.
These conditions have a significant psychological influence, proven akin to that of chronic pain, with 10% of patients with chronic psoriasis, hand eczema, or atopic dermatitis exhibiting signs of clinical depression [8, 123] . Evolutionally, the benefit of itch is thought to be the accompanying scratch which removes harmful elements from skin or fur; however, in chronic pruritic conditions this often leads to a detrimental cycle of skin changes and further scratching. Therefore, could the benefits of itch just be a remnant from our fur-coated ancestors? As we are currently unable to remove this seemingly unnecessary response from our genes, we must focus on providing safe and successful itch relief for people suffering from debilitating chronic itchy conditions. The failure to do so may leave us with an itch that we just must scratch. anti-inflammatory levels, and a disinhibited scratch response [102, 103] Ultimately, pain and itch differ in the responses they provoke; pain causes a withdrawal response, telling our body to rest, hold, or hide the affected area from external stimuli. On the contrary, itch causes the scratch response, an attentiondrawing reflex, which tells us to topically injure that area.
Would we be healthier in a scratch-free world?
Management of Pruritus
The management of pruritus is evolving toward targeted therapies tackling specific etiologies of itch. Before initiating treat- Pruritoceptive itch, if thought to be triggered by skin barrier flaws or dermatological disease, will most often be controlled via topical treatments targeting the specific skin condition and using intensive skin moisturizing regimens [17] .
Dermatological itch of urticarial origin, thought to arise from histamine release, is most often controlled with oral high-dose antihistamines, intermittent steroids, or, in refractory cases, the biological anti-IgE omalizumab [17, 113] . In refractory dermatological pruritus, disease-specific interventions, for example narrow-band phototherapy in psoriasis, can control flares; however, this must be balanced with the long-term risks of skin malignancy [114] .
Specific subtypes of itch can also be managed using therapies that directly target their transmission pathways.
Uremic pruritus has been successfully controlled using topical capsaicin or oral gabapentin [28, 59] . Nocturnal and hemato- 
